Source link : https://www.newshealth.biz/health-news/osimertinib-savolitinib-combo-shows-promise-in-nsclc/
SAN DIEGO — Combination therapy with osimertinib and savolitinib could become a novel first-line treatment option for patients with de novo MET-aberrant, EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to results of the phase 2 FLOWERS study. Compared with EGFR inhibitor osimertinib alone, the combination demonstrated a clinically meaningful improvement in the objective response […]
Author : News Health
Publish date : 2024-09-10 12:38:36
Copyright for syndicated content belongs to the linked Source.
